Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dosages for treatment with anti-egfr antibodies

A technology of antibody and use, applied in the field of preparations for anti-ErbB2 antibody treatment

Inactive Publication Date: 2008-12-31
GENENTECH INC
View PDF38 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, although ErbB2 overexpression was associated with poor prognosis, HER2-positive patients had a three-fold greater clinical response to taxanes treatment than HER2-negative patients ( Ibid )

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dosages for treatment with anti-egfr antibodies
  • Dosages for treatment with anti-egfr antibodies
  • Dosages for treatment with anti-egfr antibodies

Examples

Experimental program
Comparison scheme
Effect test

preparation example

[0289] Controlled release formulations may also be prepared. Suitable examples of controlled release formulations include semipermeable matrices of solid hydrophobic polymers containing the antibody in shaped articles such as membranes or microcapsules. Examples of controlled release formulations include polyesters, hydrogels such as poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol), polylactide (US Patent 3,773,919), L-glutamic acid and gamma ethyl - Copolymers of L-glutamate, non-degradable ethylene ethyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT TM (injectable microspheres composed of lactic-co-glycolic acid and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid can release molecules for more than 100 days, certain hydrogels release proteins for a shorter period of time. When encapsulated antibodies stay in the body for a long time, they can denat...

Embodiment 1

[0318] Example 1: HERCEPTIN Preparation and potency of anti-ErbB2 antibodies

[0319] Materials and Methods

[0320] Anti-ErbB2 monoclonal antibody According to the methods described in Fendly et al., Cancer Research 50: 1550-1558 (1990) and WO89 / 06692, anti-ErbB2 IgG specifically binding to the extracellular domain of ErbB2 was prepared 1 Kappa mouse monoclonal antibody 4D5. Briefly, NIH 3T3 / HER2-3 prepared as described by Hudziak et al. (Proc. 400 cells (approximately expressing 1×10 5 ErbB2 molecule / cell), and immunized BALB / c mice with it. At 0, 2, 5 and 7 weeks, mice were intraperitoneally injected with 10 7 0.5ml PBS for each cell. At weeks 9 and 13, specific antiserum (which can be compared with 32 P-labeled ErbB2 immunoprecipitation) mice were intraperitoneally injected with wheat germ agglutinin-Sepharose (WGA) purified ErbB2 membrane extracts. Afterwards 0.1 ml of ErbB2 preparation was injected intravenously, and the splenocytes were fused with the mou...

Embodiment 2

[0371] Embodiment 2: Anti-ErbB2 antibody (HERCEPTIN ) pharmacokinetic and pharmacodynamic properties

[0372] HERCEPTIN was administered via intravenous infusion to patients selected according to the criteria provided in Example 1 Anti-ErbB2 antibody. HERCEPTIN at an initial dose of 4 mg / kg by intravenous infusion Anti-ErbB2 antibody, followed by HERCEPTIN 2 mg / kg IV once a week for several weeks Anti-ErbB2 antibody. Of the 213 patients who started the regimen, fewer than 90 had blood levels collected over 8 weeks due to selective discontinuation of patients with rapidly progressive disease. Among the 213 patients who started treatment, the number of people whose serum trough concentration could be measured at different times was: 80 at 12 weeks, 77 at 16 weeks, 44 at 20 weeks, 51 at 24 weeks, and 51 at 28 weeks 25 at 32 weeks, 23 at 32 weeks and 37 at 36 weeks.

[0373] HERCEPTIN Trough serum concentrations of anti-ErbB2 antibodies at weeks 0-36

[0374] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.

Description

[0001] This case is a divisional application of an invention application with a filing date of August 25, 2000, a Chinese application number of 00814590.3, and an invention title of "Preparation for Anti-ErbB2 Antibody Therapy". field of invention [0002] The present invention relates to the treatment of disorders characterized by overexpression of ErbB2 or by expression of epidermal growth factor receptor (EGFR), comprising administering to a human or animal suffering from said disorder a therapeutic amount of an antibody that will bind ErbB2. More specifically, the invention relates to the treatment of human patients predisposed to or diagnosed with ErbB2-overexpressing or EGFR-expressing cancers by administering a frontal load during treatment by intravenous and / or subcutaneous administration amount of anti-ErbB2 antibody. The present invention optionally includes the use of anti-ErbB2 antibodies in combination with chemotherapeutic agents, such as but not limited to taxoi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61KC07K
Inventor 沙伦·A·鲍曼史蒂文·谢克
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com